Please read this page completely before beginning the activity. If you have any questions or need further information, please call the Memorial Sloan-Kettering Cancer Center's CME Office at 646-227-2025.
This CME activity is directed toward all physicians involved in the treatment of patients with ovarian cancer.
This activity will provide participants with an overview of consolidation therapies in ovarian cancer and the reasons why the second remission population is important to focus upon. The majority of consolidation therapies to date have been applied in first remission. The second remission population is ideal in which to study multiple new agents but there is an educational gap in that the second remission population needs further characterization. The ultimate goal of the activity is to improve the care provided to ovarian cancer patients.